Arch Biopartners Inc.
ACHFF
$1.20
-$0.061-4.84%
| Weiss Ratings | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.92 | |||
| Price History | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.33% | |||
| 30-Day Total Return | -11.19% | |||
| 60-Day Total Return | -10.52% | |||
| 90-Day Total Return | -13.12% | |||
| Year to Date Total Return | -10.52% | |||
| 1-Year Total Return | -32.07% | |||
| 2-Year Total Return | -28.63% | |||
| 3-Year Total Return | -64.10% | |||
| 5-Year Total Return | 88.82% | |||
| 52-Week High % Change | -29.29% | |||
| 52-Week Low % Change | 41.18% | |||
| Price | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.78 | |||
| 52-Week Low Price | $0.89 | |||
| 52-Week Low Price (Date) | Aug 22, 2024 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 82.98M | |||
| Enterprise Value | 85.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | 80.17% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 57.01 | |||
| Price/Book (Q) | -27.63 | |||
| Enterprise Value/Revenue (TTM) | 59.18 | |||
| Price | $1.20 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -38.42 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 64.94M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 647-428-7031 | |||
| Address | 545 King Street West Toronto, ON M5V 1M1 | |||
| Website | www.archbiopartners.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -154.04% | |||
| Profit Margin | -180.90% | |||
| Management Effectiveness | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -325.13% | |||
| Return on Equity | -- | |||
| Income Statement | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.44M | |||
| Total Revenue (TTM) | 1.44M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | -1.30M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -2.22M | |||
| Net Income (TTM) | -2.61M | |||
| Net Income Avl. to Common (TTM) | -2.61M | |||
| Total Revenue Growth (Q YOY) | -61.57% | |||
| Earnings Growth (Q YOY) | 48.34% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 50.00% | |||
| Balance Sheet | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 38.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 370.80K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.96M | |||
| Current Ratio (Q) | 0.111 | |||
| Book Value Per Share (Q) | -$0.05 | |||
| Total Assets (Q) | 370.80K | |||
| Total Current Liabilities (Q) | 3.33M | |||
| Total Debt (Q) | 2.28M | |||
| Total Liabilities (Q) | 3.33M | |||
| Total Common Equity (Q) | -2.96M | |||
| Cash Flow | ACHFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.82M | |||
| Net Change in Cash (TTM) | -185.20K | |||
| Levered Free Cash Flow (TTM) | -1.26M | |||
| Cash from Operations (TTM) | -2.00M | |||
